Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. Summary
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
70.96(c) 71.73(c) 71.38(c) 71.69(c) 71.19(c) Last
9 594 935 5 896 216 6 556 960 5 263 484 5 019 565 Volume
-0.91% +1.09% -0.49% +0.43% -0.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 25 003 M - -
Net income 2021 6 530 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,1x
Yield 2021 3,97%
Sales 2022 24 129 M - -
Net income 2022 6 737 M - -
Net Debt 2022 17 650 M - -
P/E ratio 2022 13,6x
Yield 2022 4,16%
Capitalization 89 259 M 89 259 M -
EV / Sales 2021 4,49x
EV / Sales 2022 4,43x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
Read more
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GILEAD SCIENCES, INC.
09/23GILEAD SCIENCES : Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in Hi..
AQ
09/22GILEAD SCIENCES : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Stud..
MT
09/22BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
09/22GILEAD SCIENCES : Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in H..
BU
09/22Gilead Sciences, Inc. Announces Positive Results from A Phase 3 Randomized, Double-Blin..
CI
09/20GILEAD SCIENCES : to Present Latest Antiviral Research Data Addressing Urgent Global Needs..
BU
09/20Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infe..
CI
09/17GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard of Care in..
AQ
09/17GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic Triple-Nega..
AQ
09/17Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier ..
CI
09/16GRITSTONE BIO : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5% After-Ho..
MT
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16GILEAD SCIENCES' : Late-Stage Study Shows Breast Cancer Drug May Improve Overall Survival
MT
09/16GILEAD SCIENCES : Trodelvy® Significantly Improved Quality of Life Over Standard of Care i..
BU
09/16GILEAD SCIENCES : New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Neg..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
09/23++ Analysen des Tages von Dow Jones Newswires (23.09.2021) +++
09/23ANALYSE/Markt für Corona-Behandlungen noch lange nicht abgegrast
09/22Le Veklury de Gilead réduit le risque d'hospitalisation chez les patients atteints de C..
09/22Brooklyn ImmunoTherapeutics nomme Roger Sidhu directeur médical en chef
09/16Gritstone Oncology place 5 millions d'actions pour 55 millions de dollars -- Baisse de ..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Analysis
Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,19 $
Average target price 76,21 $
Spread / Average Target 7,06%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634
BEIGENE, LTD.46.88%35 310